A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Clinical trial NCT01862081 · COMPLETED

Trial details

NCT number: NCT01862081
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer, Non-small Lung Cancer

Start date: 2013-07-16
Primary completion: 2017-06-09
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.